Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. by Taylor, C. W. et al.
Br. J. Cancer (1991), 63, 923 929
© Macmillan Press
Different mechanisms of decreased drug accumulation in doxorubicin and
mitoxantrone resistant variants of the MCF7 human breast cancer cell
line
C.W. Taylor, W.S. Dalton, P.R. Parrish, M.C. Gleason, W.T. Bellamy, F.H. Thompson,
D.J. Roe & J.M. Trent
Section ofHematology/Oncology, Department ofInternal Medicine, Arizona Cancer Center, University ofArizona, Tucson,
Arizona 85724, USA.
Summary We selected two drug resistant variants of the MCF7 human breast cancer cell line by chronic in
vitro exposure to doxorubicin (MCF7/D40 cell line) and mitoxantrone (MCF7/Mitox cell line), respectively.
The cell lines are similar in growth characteristics including doubling time, DNA synthetic phase and cell size.
Resistance to mitoxantrone conferred only partial resistance to doxorubicin; whereas resistance selected for
doxorubicin appeared to confer complete resistance to mitoxantrone. Both agents selected for cross resistance
to the Vinca alkaloids. MCF7/D40 cells display a classic-multi-drug resistance phenotype with expression of
P-glycoprotein, decreased drug accumulation relative to the parental line and reversal of drug accumulation
and drug resistance by verapamil. MCF7/Mitox cells likewise display resistance to multiple drugs, but in
contrast to MCF7/D40 cells do not express P-glycoprotein by immunoblot or RNA blot analysis. Net drug
accumulation in MCF7/Mitox cells was decreased relative to the parental cells but there was no selective
modulation of drug accumulation or in vitro drug resistance by the addition of verapamil. Efflux of
mitoxantrone was enhanced in both the MCF7/D40 and MCF7/Mitox cell lines relative to the MCF7/S cell
line. We conclude that the two drug resistant cell lines have different mechanisms of decreased drug
accumulation.
Breast cancer is responsive to a wide variety of single and
combination chemotherapy regimens. Unfortunately, after an
initial response to chemotherapy most patients with metas-
tatic breast cancer ultimately develop recurrences (Dalton,
1990). In such patients, clinical drug resistance (failure to
respond to drugs which were initially effective) is a common
phenomenon. Clinical drug resistance is likely due to a
number of factors such as tumour growth kinetics, develop-
ment of pharmacologic sanctuaries due to loss of vascular
supply, development of hypoxia in large tumours, and devel-
opment of structural and metabolic changes in individual
tumour cells.
Doxorubicin (DOX) is the most active single agent cur-
rently available for the treatment of breast cancer (Tormey,
1975). For previously treated and untreated patients the res-
ponse to DOX as a single agent varies between 28 and 43%
respectively. In addition, DOX is an integral component of
many combination chemotherapy regimens for breast cancer.
Mitoxantrone (Mitox) belongs to a new class of synthetic
chemotherapeutic agents, the anthracenediones (Alberts et
al., 1980). Numerous comparisons have been made between
DOX and Mitox in that both compounds possess dihydroxy-
quinones and are believed to intercalate DNA (Shenkenberg
& Von Hoff, 1986). Mitox is active as a single agent in
patients with breast cancer (Smyth et al., 1984; Yap et al.,
1981).
Individual tumour cells may develop resistance to a broad
range of structurally unrelated drugs and thus display the
multidrug resistance (MDR) phenotype (Gerlach et al.,
1986). A 170,000 dalton cell membrane protein, termed P-
glycoprotein is over-expressed in some MDR cells and func-
tions as a drug efflux-pump (Gerlach et al., 1986; Pastan &
Gottesman, 1987). A DOX-resistant MCF7 breast cancer cell
line (DOXR MCF7) was previously reported and shown to
have a decreased intracellular drug accumulation, over-
expression of P-glycoprotein and over-expression of an ani-
onic form of the enzyme glutathione transferase (Batist et al.,
1986; Cowan et al., 1986). Another DOX-resistant breast
cancer cell line (MDA-ADR) was found to express P-glyco-
protein gene sequences (Fuqua et al., 1987). In comparison
to DOX resistance, little has been reported about the devel-
opment and mechanisms of Mitox resistance in human
cancer cell lines. Recent reports, however, indicate that resis-
tance to Mitox in colon cancer (WiDr) and leukaemia (HL-
60) cell lines confers a unique MDR phenotype unrelated to
the over-expression of P-glycoprotein (Dalton et al., 1988;
Harker et al., 1989).
We have selected DOX and Mitox resistant variants of the
MCF7 human breast cancer cell line and provide evidence
that these two drug resistant cell lines share some similarities
in MDR phenotype and both have decreased drug accumu-
lation and enhanced drug efflux. The decrease in drug
accumulation appears to be partially responsible for the
MDR; however, the mechanisms of decreased drug accumu-
lation in the two cell lines are different.
Material and methods
Cell culture
The MCF7 parent cell line was obtained from the American
Type Culture Collection (ATCC, Rockville, MD). Authen-
ticity was confirmed by cytogenetic analysis. The MCF7 cells
were adherent to plastic and grown in RPMI 1640 medium
supplemented with 10% (v/v) foetal bovine serum,
1% (v/v) penicillin (100 units ml 1), 1% (v/v) streptomycin
(100 jig ml-'), and 1% (v/v) L-glutamine (GIBCO, Grand
Island, NY). Cells were maintained at 37°C in a 5%
C02-95% air atmosphere.
Drugs
DOX was obtained from Adria Laboratories (Columbus,
OH); Vincristine (VCR) from Eli Lilly Laboratories (Indiana-
polis, IN); Verapamil (VER) from Knoll Pharmaceuticals
(Whippany, NJ); Mitox from Lederle/Cyanamid (Pearl River,
NY); amsacrine (m-AMSA) from Ben Venue Laboratories,
Inc. (Bedford, OH). Vinblastine (VBL) and 5-fluoracil (5-FU)
were obtained from LyphoMed, Inc. (Rosemont, IL). Etopo-
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side (VP-16) and mitomycin-C (MitoC) were obtained from
Bristol Laboratories (Evansville, IN). Cisplatin (CDDP), mel-
phalan (L-PAM) and gramacidin-D (Gram-D) were obtained
from Sigma Chemicals (St. Louis, MO). 3H VCR (specific
activity of 6.2 Ci mmole ', 6.72 mCi mg-') was obtained
from the Amersham Corp. (Arlington Heights, IL); "4C DOX
(specific activity 23.3 mCi mmole 1, 40.2 yCi mg-') obtained
from SRI International (Menlo Park, CA); "4C Mitox
(specific activity 8.1 mCi mmole ', 18.2 giCi mg-') obtained
from Research Triangle Institute (Research Triangle Park,
NC).
Selection ofdrug resistant cells
MCF7 parental cells were exposed to DOX or Mitox, each at
an initial concentration of 1 x 10-8M. Fresh drug was added
when the medium was changed (approximately three times
weekly). As allowed by cell growth, the concentration of each
drug was slowly increased in a multiple step procedure. Over
a period of 19 months the concentration of DOX was in-
creased from 1 x 10-8M to 7 x 10-8M. An additional 12
months were required to reach the final DOX concentration
(4 x 10-7M, representing a 40-fold increase) and full develop-
ment of the DOX resistant variant (MCF7/D40) for a total
selection time of 31 months. The Mitox resistant cell line
(MCF7/Mitox) was selected in a similar fashion by increasing
the Mitox concentration from 1 x 10-8M to 8 x 10-8M over a
6 month period.and maintaining this concentration over the
next 18 months. Prior to any experiments, cells were main-
tained in drug-free medium for I week.
In vitro drug assays
Cytotoxicity was determined using a modified MTT (3-(4,5-
dimethylthlazol-2-yl)-2,5-diphenyl tetrazolium) dye assay
(Carmichael et al., 1987; Denizot & Lang, 1986). This is a
colorimetric assay based on the ability of viable cells to
reduce MTT to a blue formazan product. In dose response
curves the data are presented as the per cent of an optical
density value obtained for untreated cells. Cells were plated
into 96-well microtiter plates (Falcon, Becton Dickinson and
Company, Oxnard, CA) at 1 x 104 cells/well in 0.2 ml of
media containing appropriate concentration of drug with
replicates of six (standard deviations were within ± 10% of
the mean values) VER (6 ,g ml-', 13.2pM) was added
15 min prior to drug and was present continuously during
the period of incubation with drug. After incubation for 4
days at 37°C, 501l of MTT dye (2 mgml-') was added to
each well and incubated for 4 h. Plates were then centrifuged
at 500g for 5 min, media aspirated, dimethyl sulfoxide
(DMSO) added to each well (100 tlI), plates mechanically
agitated for 5 min and optical density at 570 nm determined
on a microplate reader (Dynatech Labs, Alexandria, VA).
Each experiment was repeated a minimum of three times and
data from a representative experiment are shown. A
clonogenic assay (Malinin & Perry, 1967) was used to
confirm results obtained with the MTT assay for Mitox with
and without VER. The concentration of drug which pro-
duced a 50% inhibition of cloning efficiency (ICs) was cal-
culated by linear regression analysis of the linear portion of
the dose response curves.
Cellgrowth characteristics
For the determination of doubling time, cell growth curves
were established for each cell line by plotting cell number
versus growth time. Doubling time was determined directly
from the linear portion of the plot. The fraction of cells in
S-phase and relative cell size were determined using flow
cytometry (FACStar Flow Cytometer, Becton Dickinson)
after propidium iodide staining (Krishan, 1975; Deitch et al.,
1982). Actual tumour cell diameters were determined by
direct measurements of 100 tumour cells per cell line using an
inverted microscope equipped with a reticle and an internal
standard. The results are expressed as the mean cell diameter
and the standard deviation.
Chromosome analysis
Cultures were harvested for karyotypic analysis, slides pre-
pared and G-banding performed as previously described
(Trent & Thompson, 1987). A minimum of 30 cells per cell
line were analysed, with results expressed according to ISCN
recommendations (Harden & Klinger, 1985). Karyotypic in-
formation on the parental MCF7 cell line has been presented
previously (Osborn et al., 1987).
Drug accumulation
Cellular accumulation of drug was determined during a 1 h
exposure of an aliquot of cells (1 x 106 cells plated 2 days
previously into a 35 mm2 petri dish) to "'C DOX-5.0tM, "1C
Mitox-10.01M, and 3H VCR-1.GgM at 37°C. These drug
concentrations were chosen based on the relative specific
activities of the three radiolabelled agents in an attempt to
achieve similar counts per minute (c.p.m.) in MCF7/S cells.
One hour after the addition of radiolabelled drug, the cells
were washed twice with ice cold phosphate buffered saline
(PBS) trypsinised, incubated with 0.2 N NaOH for 2 h and
neutralised with 0.2 N HCI (equivalent volumes). The amount
of radiolabel (c.p.m.) was determined using liquid scintilla-
tion counting. Each experiment was repeated a minimum of
three times and data from a representative experiment are
shown.
For all experiments involving VER, cells were incubated in
media containing 6ggml-' (13.2jLM) VER for 15 min prior
to drug exposure and during the 1 h drug exposure.
Mitoxantrone efflux studies
Cells were incubated with "'C Mitox for 1 h as described in
the Drug Accumulation section. At the end of 1 h, cells were
placed on ice and washed once with ice cold PBS; drug-free
RPMI complete media (2% foetal bovine serum) was added,
and cells were incubated at 37°C for up to 60 min. At the end
of each time period, cells were washed, trypsinised, digested,
and counted as described previously. Efflux at each time
point was determined by:
c.p.m. "'C Mitox
c.p.m. "'C Mitox at time 0
Each experiment was repeated a minimum of three times
and data from a representative experiment are shown.
Non-protein sulJhydryl (NPSH) measurements
The NPSH content of the MCF7 cell lines was measured
using the method of Sedlak and Lindsay (1968). A total of
5 x 10' cells was washed twice with iced PBS (pH 7.4) and
transfered to a microcentrifuge tube where they were lysed by
sonication (model 250 Branson sonifier, Danbury, CT). Cel-
lular protein was precipitated by addition of 5% sulfosal-
icylic acid. The cell lysate was then centrifuged at 12,000g
for 5 min at room temperature and a 1 ml aliquot of the
supernatant was transferred to a tube containing 0.2 M Tris
buffer (pH 8.9). To each tube, 100ftl of 0.01 N 5,5'-dith-
iobis(2-nitrobenzoic acid) in absolute methanol was added.
The contents were mixed and the absorbance of each sample
was measured at 412 nm. The concentration of NPSH in the
sample was determined by comparing the optical density
reading of the sample to a standard curve constructed using
reduced glutathione. NPSH levels were analysed 4 days post
cell passage in all lines. Protein measurements were deter-
mined according to the method of Lowry et al. (1951).
Immunoblot analysisfor P-glycoprotein
Plasma membranes were purified from 2 x 108 cells (Riordan
& Ling, 1979). Polyacrylamide gel electrophoresis (50fig pro-
tein per lane) was performed according to the method of
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cyl sulphate-polyacrylamide gels onto nitrocellulose filter
paper according to the method of Towbin et al. (1979). The
nitrocellulose filters were then incubated overnight at room
temperature in tris-PBS (TPBS) containing the C219 mono-
clonal antibody (IgG) (kindly provided by Dr Victor Ling,
Ontario Cancer Institute, Toronto, Ontario, Canada) at a
concentration of 10 ng ml-' (Kartner et al., 1985). Following
wash steps to remove unbound antibody, the filters were
incubated overnight at room temperature in 50 ml of TPBS
containing 25 fig of 1231-labelled rabbit anti-mouse IgG (spec-
ific activity 600 ACi ml-', New England Nuclear, Boston,
MA). The filters were again washed to remove the unbound
secondary antibody, dried, and exposed to X-Omat AR film
(Kodak). A membrane preparation from 8226/DOX40 multi-
ple myeloma cells was added as a positive control for P-
glycoprotein (Dalton et al., 1986).
RNA analysis
RNA was isolated from MCF7 cells using guanidium isothio-
cynate and cesium chloride centrifugation (Maniatis et al.,
1982). Slot blot analysis of total cellular RNA was carried
out as described (Davis et al., 1986) using a 640 bp cDNA
fragment of mdr-1, p-CHP-1, isolated from a colchicine-
resistant CHO cDNA library (Riordan et al., 1985). The
probe was oligolabelled according to the method of Feinberg
and Vogelstein (1983). Human multiple myeloma cells dis-
playing the multidrug resistant phenotype (8226/DOX40)
were included as positive controls and the drug sensitive
parent cells (8226/S) as negative controls. The blots were also
probed with 32P-labelled human tubulin cDNA (American
Type Culture Collection, Rockville, MD) to confirm the
amount of RNA contained in each sample.
Statistical methods
The P-values for the comparison of drug accumulation with
and without VER were calculated using a two-sample inde-
pendent t-test. The P-values for the difference in drug
accumulation between cell lines were calculated using Tukey's
Studentised Range Test and the Bonferroni multiple com-
parisons procedure (Miller, 1981). The 95% confidence limits
of the doubling times were determined from the slope of the
linear portion of the growth curves (Mood et al., 1974). The
slopes of the Mitox efflux curves were evaluated by Analysis
of Covariance (Snedecor & Cochran, 1980).
Results
Growth characteristics
The growth characteristics of the sensitive, parental line
(MCF7/S), DOX resistant variant (MCF7/D40) and Mitox
resistant variant (MCF7/Mitox) are listed in Table I. The
doubling times for MCF7/S, MCF7/D40 and MCF7/Mitox
cells were similar. No differences between the fraction of cells
in S-phase were demonstrated between the three cell lines.
The mean cell diameter varied slightly among the three cell
lines, but the confidence intervals (standard deviation) were
overlapping.
Dose response curves
Dose response curves for MCF7/S and MCF7/D40 cells after
exposure to DOX (with and without VER) as determined by
the MTT assay are depicted in Figure la. Similar curves for
MCF7/Mitox cells after exposure to Mitox (with and without
VER) are depicted in Figure lb. Significant resistance to
DOX and Mitox was observed for both MCF7/D40 and
MCF7/Mitox cells, respectively. However, the addition of
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Figure 1 Dose response of MCF7/S (0) and MCF7/D40 (-)
cells to DOX alone (close symbols) and in combination with
VER (open symbols) (VER-61igml', 13.2iLM, MTT assay) (a).
Dose response of MCF7/S (0) and MCF7/Mitox (U) cells to
Mitox alone (closed symbols) and in combination with VER
(open symbols) (VER-6jLgml-', 13.2I1M, MTT assay) (b). The
data are presented as the per cent of control optical density
(o.d.).
Table I Growth characteristics
Cell line
Characteristic MCF7/S MCF7/D40 MCF7/Mitox
Doubling time, hours 41.6 35.2 40.3
(95% confidence (32.1-59.0) (25.5-56.8) (35.0-47.6)
limits)
aFraction of cells in 38% 38% 31%
S-phase
bRelative cell 1.00 1.09 1.00
size
Mean cell diameter in 18.5 21.0 17.5
microns (SD) (3.5) (6.1) (3.0)
aDetermined using propidium iodide and flow cytometry. bDetermined using flow
cytometry, MCF7/S normalised to 1.00.926 C.W. TAYLOR et al.
VER affected resistance only for the MCF7/D40 cell line.
VER alone was minimally toxic to the cells (data not shown).
The 50% inhibitory concentration (IC50) of DOX (with and
without VER) against MCF7/D40 cells and the IC50 of Mitox
(with and without VER) against MCF7/Mitox cells are
shown in Table II. With the addition of VER the IC50 of
DOX against MCF7/D40 cells decreased 10-fold (30 uM vs
3.1 SAM). In contrast, the IC50 of Mitox against MCF7/Mitox
cells was essentially unchanged with VER exposure (64tLM vs
91 pM). The experiments performed with the MTT assay
were repeated using a clonogenic assay (Malinin & Perry,
1967) for Mitox with and without VER in all three cell lines
(Table II). The IC50s from the clonogenic assays were gen-
erally lower than those obtained from the MTT assays.
However, the relative degree of resistance between the cell
lines was similar. In addition, the IC50 from the clonogenic
assay for Mitox against MCF7/Mitox cells remains un-
changed with VER exposure (7.7 jiM vs 7.4 jiM).
Cross resistance patterns
Table II demonstrates the sensitivities of the 3 MCF7 cell
lines to a number of chemotherapeutic agents. The data are
expressed as the IC50 and as the relative amount of resistance
of MCF7/D40 and MCF7/Mitox cells to MCF7/S cells (IC50
ratio). A high degree (75 fold) of resistance to DOX was
observed in MCF7/D40 cells. In addition, MCF7/D40 cells
were cross resistant to a number of other drugs: VCR (190
fold), Mitox (153 fold), VLB (93 fold), m-AMSA (41 fold).
The addition of VER partially reversed the resistance of
MCF7/D40 cells to DOX, VCR and Mitox.
MCF7/Mitox cells displayed a very high degree of resis-
Table II Cross resistance patterns
IC50a, AM
(IC50ratiob)
Drug MCF7/S MCF7/D40 MCF7/Mitox
DOXC 0.4 30 3.3
(75) (8.3)
DOX + VER 0.37 3.1 3.5
(8.4) (9.5)
VCR 0.0039 0.74 0.086
(190) (22)
VCR + VER 0.0031 0.065 0.16
(21) (52)
Mitox 0.053 8.1 64
(153) (1208)
[O.01 1]d [0.14] [7.7]
Mitox + VER 0.053 1.2 91
(23) (1717)
[0.0071] [0.034] [7.4]
VLB 0.0070 0.65 0.30
(93) (43)
CDDP 1.3 6 28
(4.6) (21.5)
VP-16 2.9 33 76
(11) (26)
m-AMSA 0.86 35 36
(41) (42)
L-PAM 16 40 91.4
(2.5) (5.7)
MitoC 0.72 5.3 6.3
(7.4) (8.8)
Gram D 0.15 gml-' 1.2jgml-' 0.98 1gml-'
(8) (6.5) 5FU 30 103 117
(3.4) (3.9)
'50% Inhibitory Concentration, asdetermined by MTTassay; bRatio
of IC50 for the drug resistant cell line to MCF7/S; cAbbreviations:
DOX = Doxorubicin VP-16 = Etoposide
VCR = Vincristine m-AMSA = Amsacrine
VER = Verapamil L-PAM = Melphalan
Mitox = Mitoxantrone MitoC = Mictomycin C
VLB = Vinblastine Gram D = Gramacidin D
CDDP = Cisplatinum SFU = 5-Fluorouracil; d[] = IC50 as determined by clonogenic assay.
tance to Mitox (1208 fold) which was not reversed by VER.
A lesser degree of cross resistance to DOX (8.3 fold) and
VCR (22 fold) was observed. VER was ineffective in revers-
ing resistance to both DOX and VCR in MCF7/Mitox cells.
The MCF7/Mitox cell line was cross resistant to VLB (43
fold), m-AMSA (42 fold) VP-16 (26 fold) and CDDP (21.5
fold). Only low levels of resistance to L-PAM, MitoC, Gram
D or 5FU were seen in either MCF7/D40 or MCF7/Mitox
cells.
Drug accumulation studies
The 1 h net intracellular accumlations of 14C DOX, 3H VCR
and '4C Mitox are displayed in Figure 2. In both the MCF7/
D40 and MCF7/Mitox cell line, accumulation of 14C DOX
(Figure 2a), 3H VCR (Figure 2b) and "4C Mitox (Figure 2c)
was decreased relative to the MCF7/S cell line. The MCF7/
Mitox cell line had less net intracellular drug accumulation
for DOX and Mitox compared to the MCF7/D40 cell line
(P<0.05 for DOX and Mitox) and the MCF7/S parent cell
line (P<0.05 for DOX and Mitox). Both resistant cell lines
had decreased VCR net intracellular accumulation relative to
MCF7/S (P<0.05 for MCF7/D40 and MCF7/Mitox) but
were not different from each other (P>0.05).
The effects of VER in increasing DOX and VCR intracel-
lular drug accumulation were limited to the MCF7/D40 resis-
tant cell line (41% and 298% increased, respectively) with no
effect observed in the MCF7/S or MCF7/Mitox cell lines. A
slight but significant increase in Mitox accumulation was
seen in both the MCF7/S (25%) and MCF7/Mitox (24%)
cell lines with a greater increase seen in the MCF7/D40 cell
line (63%).
Curves of Mitox efflux versus time in minutes for MCF7/S,
MCF7/D40 and MCF7/Mitox cells were depicted in Figure
3. At each time point tested, relatively less drug persisted in
MCF7/Mitox and MCF7/D40 cells as compared with
MCF7/S cells. At the 5min time point MCF7/D40 and
MCF7/Mitox cells contained 34% (2149 c.p.m.) and 24%
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Figure 2 One hour net accumulation of "1C DOX (5.0pM), 3H
VCR (1.0IM) and 1'C Mitox (10.0 JM) in MCF7/S, MCF7/D40
and MCF7/Mitox cells with (closed bars) and without (open
bars) VER (6 jig/ml- '), 13.21AM). Error bars indicate the standard
error of the mean with replicates of three. P-values for the effect
of VER are indicated above the respective open and closed bars.
The decreased accumulation of each of the three drugs alone in
MCF7/D40 and MCF7/Mitox cells relative to MCF7/S cells were
statistically significant (P<0.05 in each instance).DRUG ACCUMULATION IN RESISTANT MCF7 BREAST CANCER CELLS 927
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Figure 3 Efflux of Mitox in MCF7/S (0), MCF7/D40 (A) and
MCF7/Mitox (v) cells versus time (minutes). Data points are
expressed as per cent of 14C Mitox present at time 0. Error bars
indicate the standard error of the mean with replicates of three.
(1526 c.p.m.) respectively, of the amount of drug contained
in MCF7/S cells (6299 c.p.m.). These values were statistically
significant at P<0.05 for MCF7/S cells compared to both
MCF7/D40 and MCF7/Mitox cells. Furthermore, in MCF7/
Mitox and MCF7/D40 cells drug efflux was more rapide
during the initial 5 min as compared to MCF7/S cells. Statis-
tical comparison of the slopes of the efflux curves during this
time period revealed P = 0.055 and 0.0063 for MCF7/S cells
compared to MCF7/D40 and MCF7/Mitox cells, respec-
tively. At time points beyond 10 min the slopes of the efflux
curves were not significantly different.
P-glycoprotein detection
An immunoblot probed for the presence of P-glycoprotein
using the C219 antibody is seen in Figure 4. The 8226/
DOX40 cell line was included as a positive control for P-
glycoprotein (Dalton et al., 1986). P-glycoprotein was detec-
ted in the MCF7/D40 cell line but was not seen in the
MCF7/S and MCF7/Mitox cell lines.
RNA analysis
Slot blot analysis revealed no evidence of mdr-1 message in
the MCF7/S or MCF7/Mitox cell lines but was found to be
expressed in the MCF7/D40 line thus confirming our findings
using western blotting (Figure 5). Thus, selection with the
anthracycline DOX resulted in an expression of the P-
glycoprotein message while selection with the antracenedione
mitoxantrone did not.
97.4-
68-
Figure 4 Immunoblot for the presence of P-glycoprotein (C219
antibody) in MCF7/S, MCF7/Mitox and MCF7/D40 cells (8226/
DOX40 cell line - positive control).
Cytogenetic studies
Chromosomal analysis of the MCF7 parent cell line and its
DOX and Mitox resistant sublines were performed using
G-banding analysis. Detailed cytogenetic analysis of the
parental line has been published previously (Osborne et al.,
1987). There were obvious similarities between all three cell
lines clearly indicating their common origin. All three cell
lines demonstrated a near-triploid chromosome number
(72-80) with numerous structural and numeric alterations
(Table III). The MCF7/D40 cell line deviated the most
significantly from the parental cell line (primarily by the
addition of new marker chromosomes). The MCF7/Mitox
cell line more closely resembled the parental line with the
only differences being a loss of the marker chromosomes
lp-, 6q-, 7pHSR, 13q+, 16q+ and the addition of one
marker unique to this cell line (3p+). The parental cell line
(which is known to be amplified for N-ras) (Graham et al.,
1985) displayed cytologic evidence of gene amplification in
the form of a homogeneous staining region. This marker was
lost in both resistant sublines and neither displayed double
minutes or other HSRs.
8226/S
8226/DOX40
MCF7/S
MCF7/D40
MCF7/MITOX
Figure 5 Slot blot analysis of MCF7 RNA. Serial two-fold dilutions of total cellular RNA (10, 5, 2.5, 1.25, 0.6, 0.3 fig, left to
right) were applied to the filter. After hybridisation with the p-CHP-l cDNA probe, the filter was exposed for 24 h with an
intensifying screen at - 80C.
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Table III Cytogenetic analysis of MCF7 parental and resistant
sublines
Marker MCF7/S MCF7/D40 MCF7/Mitox
lp- +
2q+ + +
der(2) +
2q- +
3p- + + +
3p+ +
5p+ + + +
6p+ +
6q+ + + +
6q- + +
7p+ + +
7pHSR +
inv(7) + + +
9p+ +
12q- + + +
13q+ + +
16q+ +
17q+ +
t(l2;19) + + +
t(22;22) +
Xq- + +
Xq+ +
t(X;?) +
Non-protein sulfhydryl (NPSH) measurements
The MCF7/S cell line was found to have significantly ele-
vated amounts of NPSH compared to the other two cell lines
(25.43 ± 0.34 nmol 10-6 cells; P<0.001; Student's t-test).
NPSH levels in MCF7/D40 and MCF7/Mitox cells were
decreased at 16.23 ± 0.28 and 15.83 ± 0.21 nmol 10-6 cells
respectively (not significant, Student's t-test). Total protein
measurements revealed no differences among the three cell
lines (data not shown).
Discussion
In this report we describe the development of two multidrug-
resistant cell lines established from a common parental cell
line using DOX and Mitox as selecting agents. Of note is the
fact that Mitox resistance developed much quicker (6
months) than DOX resistance (greater than 2 years). In
establishing the drug resistant variants the concentrations of
the selecting agents were increased as rapidly as allowed by
cell growth. Indeed, the concentration of DOX could be
increased only very slowly in the selection of the MCF7/
DOX cell line. However, in spite of a different degree of
selection pressure for the MCF7/Mitox cell line (lower final
Mitox concentration, shorter selection time) relative to the
MCF7/DOX cell line, a greater degree of Mitox resistance
(1208 fold vs 75 fold) developed. Formal fluctuation analysis
tests were not performed and the rate of mutation to resis-
tance for the individual drugs cannot be stated.
The DOX resistant (MCF7/D40) and Mitox resistant
(MCF7/Mitox) cell lines have both similarities and differ-
ences in cross resistance to other agents. A broad range of
drugs with varied mechanisms of action were studied: DNA
binding/intercalating agents (DOX, Mitox), tubulin binding
agents (VCR, VLB), alkylating agents (L-PAM, CDDP,
Mito-C) topoisomerase II inhibitors (DOX, Mitox, VP-16,
m-AMSA), an antimetabolite (5 FU) and a cell membrane
ionophore (Gram-D). In addition to being resistant to DOX,
MCF7/D40 cells were highly resistant to the tubulin binding
agents, moderately resistant to the topoisomerase agents and
displayed lower levels of resistance to the alkylating agents
and the antimetabolite 5 FU. Cross-resistance to Mitox was
also high in the MCF7/D40 cell line. The MCF7/Mitox cell
line displayed a number of unique characteristics. It devel-
oped a very high degree of resistance (1208 fold) to the
primary selecting agent (Mitox) with relatively minor cross
resistance to DOX (8.3 fold) and VCR (22 fold). In addition,
MCF7/Mitox cells were partially cross resistant to CDDP, an
agent not commonly associated with the multidrug-resistance
phenotype (21.5 fold resistant).
Other Mitox resistant cell lines have been reported and are
similar to the Mitox resistant MCF7 cell line in that P-
glycoprotein is not over-expressed. Wallace et al. first repor-
ted a human colon carcinoma cell line selected for resistance
to Mitox (WiDr) (Wallace et al., 1987). This line was further
characterised by Dalton et al. demonstrating decreased in-
tracellular accumulation of both Mitox and DOX with no
increased expression of P-glycoprotein (Dalton et al., 1988).
Harker et al. recently reported an HL-60 leukaemic cell line
selected for resistance to Mitox which also lacked P-glyco-
protein overexpression (Harker et al., 1989).
Marsh et al. reported a multi-drug resistant HL-60 cell line
which over-expressed a 150,000 dalton membrane protein
distinct from P-glycoprotein (Marsh & Center, 1988). These
investigators felt that the P150 protein was involved in the
resistance mechanism and contributed to the decreased in-
tracellular drug accumulation. Whether the Mitox resistant
cell lines over-express a novel drug-resistance related mem-
brane protein remains to be determined. Studies are currently
in progress to further describe the mechanism of enhanced
drug efflux in the MCF7/Mitox cell line.
Other drug resistance mechanisms unrelated to drug trans-
port may be important in conferring drug resistance. A
number of 'atypical' MDR cell lines have recently been
reported. Danks et al. reported a leukaemic cell line (CEM/
VM-1) selected for resistance to the epipodophyllotoxin, VM-
26 (Danks et al., 1987). This cell line was felt to display
'atypical' MDR because it was not cross resistant to Vinca
alkaloids and did not display a decreased cellular accumula-
tion of drug. Slovak et al. reported two DOX resistant cell
lines which had different mechanisms of resistance; one
associated with P-glycoprotein, the other more atypical in its
mechanism of resistance (Slovak et al., 1988). Mirski et al.
reported a DOX resistant human small cell lung cancer cell
line (Mirski et al., 1987) which displayed a typical cross
resistance pattern to VP-16, Vinca alkaloids and colchicine
but did not over-express P-glycoprotein.
In summary, this study demonstrates that two compounds
(DOX and Mitox) with structural similarities result in diff-
erent mechanisms of resistance when used as selecting agents
in the same human breast cancer cell line. Reduced drug
accumulation secondary to enhanced drug efflux accounts, at
least in part, for the multidrug resistant phenotype in both
resistant cell lines. However, only the DOX resistant cell line
over-expresses P-glycoprotein compared to the drug sensitive
parent cell line. It remains to be determined why DOX, a
natural product, induces P-glycoprotein mediated MDR;
whereas, Mitox, a synthetic compound induces a different
mechanism of MDR.
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